EUVIMEDEUVIMED entdecken
Crossref

In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion

The Medical Letter on Drugs and Therapeutics · 30.03.2026 · 68 (1751) · 56-56

DOI: 10.58347/tml.2026.1751b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 30.03.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Schlagwörter

Stichwörter der Autor:innen

Eyleaadverse effectsafliberceptdosageefficacyeyesafety

Zitieren

APA

(2026). In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion. The Medical Letter on Drugs and Therapeutics, 68(1751), 56-56. https://doi.org/10.58347/tml.2026.1751b

Vancouver

In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion. The Medical Letter on Drugs and Therapeutics. 2026;68(1751):56-56. doi:10.58347/tml.2026.1751b

BibTeX
@article{euvimed2026,
  title = {In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1751},
  pages = {56--56},
  doi = {10.58347/tml.2026.1751b}
}
Kostenlos starten →